Ben Cannon

Ben Cannon is Co-Founder of Cue Growth, a healthcare investment firm focused on transformative medical technologies. He brings deep expertise in cardiovascular and vascular devices, with a track record of backing disruptive innovations. Cue Growth co-led Field Medical’s Series B in pulsed field ablation for ventricular tachycardia and previously co-led Amplitude Vascular Systems’ $35 million Series B, supporting its novel lithotripsy platform now in Pivotal IDE trials and expanding into coronary and carotid indications.

​

Mr. Cannon serves on the Business Advisory Board of BioStar Capital, a medtech-focused venture firm with a 20-year track record in cardiology, microsurgical robotics, neurovascular, and orthopedics. Prior to founding Cue Growth, he spent 12 years at top-tier private equity and venture capital firms, including as a Principal in Healthcare at a $250 billion AUM firm, after starting his career as a Wall Street healthcare analyst.

​

Ben lives in the New York City area with his wife and three children, who remain his greatest joy.